# US 2025/0205283 A1 · Natural killer cells produced from induced pluripotent stem cells, method for producing same, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205283 A1
- Document ID: US20250205283A1
- Status: Published application
- Kind: A1
- Application number: 18/852,071
- Filed: 2023-03-31
- Published: 2025-06-26
- Earliest claimed: 2022-04-01
- Assignees: Therabest Co., Ltd
- Applicants: Therabest Co., Ltd.
- Inventors: Shin-Il Kim; Do Won Hwang; Young Wook Ki
- Web page: https://patentgrep.com/patent/US20250205283A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61P 31/12: Antivirals
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/42: Cancer antigens
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C12N 2500/05: Inorganic components
- C12N 2500/38: Vitamins
- C12N 2500/44: Thiols, e.g. mercaptoethanol
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2513/00: 3D culture
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to: natural killer cells produced and mass-proliferated from induced pluripotent stem cells; and a pharmaceutical composition comprising the same as an active ingredient. The natural killer cells according to the present invention exhibited oncolytic activity at cellular and animal levels. In addition, the expression of genes and cytokines involved in tumor death and immune cell activity was increased compared to natural killer cells isolated from blood and activated. It was also confirmed that a method for inducing differentiation of natural killer cells derived from induced pluripotent stem cells, according to the present invention, is a method for producing a large number of cells within a short period of time by using a simple method compared to conventional induction methods using induced pluripotent stem cells. Therefore, it is considered that a method for differentiating natural killer cells derived from induced pluripotent stem cells, and natural killer cells produced by the method, according to the present invention, can be used in the treatment of various diseases, including cancer.

## Claims

### Claim 1

A natural killer cell expressing any one protein selected from the group consisting of CD25, CD9, CD80, and a combination thereof.

### Claim 2 (depends on 1)

The natural killer cell according to claim 1, wherein the natural killer cell additionally expresses any one protein selected from the group consisting of CD1d, CD30, CD87, CDw327, CD33, CD49a, CD49c, CD49e, CD49f, CD66a, CD66c, CD66d, CD66e, CD71, CD83, CDw93, CD106, CD108, CD114, CD123, CD124, CD146, CD150, CD164, CD196, CD210, and a combination thereof.

### Claim 3 (depends on 1)

The natural killer cell according to claim 1, wherein the natural killer cell expresses any one natural killer cell marker protein selected from the group consisting of CD56, CD45, CD16, NKp30, NKp44, NKG2D, DNAM1, and a combination thereof.

### Claim 4 (depends on 1, 2)

The natural killer cell according to claim 1, wherein the natural killer cell is characterized by an increased expression of the protein of claim 1 or 2 compared to a natural killer cell isolated from blood.

### Claim 5 (depends on 4)

The natural killer cell according to claim 4, wherein the expression of the protein is increased by at least two times compared to a natural killer cell isolated from blood.

### Claim 6 (depends on 1)

The natural killer cell according to claim 1, wherein the natural killer cell is characterized by an additional increase in the expression of any one gene selected from the group consisting of GZMB, CD226, RASGRP1, CD107a, CCR9, CD40LG, CD300c, and a combination thereof compared to a natural killer cell isolated from blood.

### Claim 7 (depends on 1)

The natural killer cell according to claim 1, wherein the natural killer cell is characterized by an increase in the secretion of any one protein selected from the group consisting of FLT3L, MIP1alpha/beta, PF4, IGFBP2, IGFBP3, MMP9, and a combination thereof compared to a natural killer cell isolated from blood

### Claim 8 (depends on 7)

The natural killer cell according to claim 7, wherein the secretion of the protein is increased by at least two times compared to a natural killer cell isolated from blood.

### Claim 9 (depends on 1)

The natural killer cell according to claim 1, wherein the natural killer cell does not additionally express or expresses at a low rate any one protein selected from the group consisting of CD205, CD158b, CD243, γδTCR, NKB1, CD158a, CDw328, TIM3, TIGIT, and a combination thereof compared to a natural killer cell isolated from blood.

### Claim 10 (depends on 9)

The natural killer cell according to claim 9, wherein the expression of the protein is reduced by at least two times compared to a natural killer cell isolated from blood.

### Claim 11 (depends on 1)

The natural killer cell according to claim 1, wherein the natural killer cell does not express CD3, a marker protein of T cells.

### Claim 12 (depends on 1)

The natural killer cell according to claim 1, wherein the natural killer cell is differentiated from an induced pluripotent stem cell (iPSC).

### Claim 13 (depends on 12)

The natural killer cell according to claim 12, wherein the natural killer cell is produced by a method for producing natural killer cells, comprising:
inoculating induced pluripotent stem cells (iPSCs) as iPSCs or iPSC spheroids into a cell culture vessel so that 0.5 to 20 colonies are formed per 1 cm2 of cell culture vessel area and performing adhesion culture to produce iPSC colonies;
differentiating the iPSC colonies into mesodermal cells to produce mesodermal cells;
differentiating the mesodermal cells into hematopoietic stem cells to produce hematopoietic stem cells; and
differentiating the hematopoietic stem cells into natural killer cells to produce natural killer cells.

### Claim 14 (depends on 13)

The natural killer cell according to claim 13, wherein the inoculated iPSCs are inoculated at 1 to 8 iPSCs per 1 cm2 of cell culture vessel area.

### Claim 15 (depends on 13)

The natural killer cell according to claim 13, wherein the inoculated spheroids are inoculated at 1 to 8 spheroids per 1 cm2 of cell culture vessel area.

### Claim 16 (depends on 13)

The natural killer cell according to claim 13, wherein the total number of stem cells on the start date of differentiation is 1×103 to 1×106 cells per 1 cm2 of cell culture vessel area.

### Claim 17 (depends on 13)

The natural killer cell according to claim 13, wherein the cells adhered to the culture vessel are not removed in the differentiating the mesodermal cells into hematopoietic stem cells.

### Claim 18 (depends on 13)

The natural killer cell according to claim 13, wherein the cell differentiated from the mesodermal cell into a hematopoietic stem cell has a CD34 protein expression rate of 85% or more without a CD34 positive cell sorting process.

### Claim 19 (depends on 13)

The natural killer cell according to claim 13, wherein the natural killer cell is produced by additionally performing a mass culture proliferation on the natural killer cell induced to differentiate.

### Claim 20 (depends on 19)

The natural killer cell according to claim 19, wherein the mass culture proliferation is culturing the natural killer cell induced to differentiate, in a medium comprising SCF (stem cell factor), FLT3L (FMS-like tyrosine kinase 3 ligand), IL-7, IL-15, IL-2, or a combination thereof.

### Claim 21 (depends on 19)

The natural killer cell according to claim 19, wherein the mass culture proliferation is culturing the natural killer cell induced to differentiate, in a medium comprising 3-mercaptoethanol, sodium selenite, ethanolamine, L-ascorbic acid, or a combination thereof.

### Claim 22 (depends on 19)

The natural killer cell according to claim 19, wherein the mass culture proliferation of the natural killer cell induced to differentiate is performed for 1 day to 9 weeks.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A cell therapeutic agent comprising the natural killer cell according to any one of claims 1 to 22 as an active ingredient.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A pharmaceutical composition for preventing and treating a disease, comprising the natural killer cell according to any one of claims 1 to 22 as an active ingredient.

### Claim 25 (depends on 24)

The pharmaceutical composition for preventing and treating a disease according to claim 24, wherein the disease is any one selected from the group consisting of an infectious disease, cancer, a neurological disease, and an autoimmune disease

### Claim 26 (depends on 25)

The pharmaceutical composition for preventing and treating a disease according to claim 25, wherein the infectious disease is any one selected from the group consisting of hepatitis B, hepatitis C, human papilloma virus (HPV) infection, cytomegalovirus infection, viral respiratory disease, and influenza.

### Claim 27 (depends on 25)

The pharmaceutical composition for preventing and treating a disease according to claim 25, wherein the cancer is any one selected from the group consisting of liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, colorectal cancer, cervical cancer, thyroid cancer, laryngeal cancer, leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, and lymphoma.

### Claim 28 (depends on 25)

The pharmaceutical composition for preventing and treating a disease according to claim 25, wherein the neurological disease is a neurological disease caused by nerve damage or abnormal nerve, or a degenerative brain disease.

### Claim 29 (depends on 28)

The pharmaceutical composition for preventing and treating a disease according to claim 28, wherein the nerve damage is any one selected from the group consisting of neuropraxia, axonotmesis, and neurotmesis.

### Claim 30 (depends on 28)

The pharmaceutical composition for preventing and treating a disease according to claim 28, wherein the neurological disease caused by nerve damage or abnormal nerve is a neurological disease caused by nerve damage or abnormal nerve in the central nervous system, or a neurological disease caused by nerve damage or abnormal nerve in the peripheral nervous system.

### Claim 31 (depends on 30)

The pharmaceutical composition for preventing and treating a disease according to claim 30, wherein the neurological disease caused by nerve damage or abnormal nerve in the central nervous system is any one selected from the group consisting of an organic disease and dysfunction in the central nervous system, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Lewy body dementia, Huntington's disease, Parkinson's disease, schizophrenia, traumatic brain injury, stroke, Pick's disease, Creutzfeldt-Jakob disease, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, spinocerebellar degeneration, cerebellar atrophy, posttraumatic stress disorder, amnesia, vascular dementia, and cerebral infarction.

### Claim 32 (depends on 30)

The pharmaceutical composition for preventing and treating a disease according to claim 30, wherein the neurological disease caused by nerve damage or abnormal nerve in the peripheral nervous system is any one selected from the group consisting of peripheral neuropathy, diabetic neuropathy, peripheral neuropathic pain, peripheral neuropathy due to anticancer chemotherapy, complex regional pain syndrome, optic neuropathy, mononeuropathy, multiple mononeuropathy (mononeuritis multiplex), polyneuropathy, Guillain-Barré syndrome (acute inflammatory demyelinating polyneuropathy), chronic inflammatory demyelinating polyneuropathy, hereditary neuropathy, plexus disorder, glaucoma, macular degeneration, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, poliomyelitis, post-polio syndrome, stiff person syndrome, Isaacs' syndrome, myasthenia gravis, neonatal myasthenia, botulism, Eaton-Lambert syndrome, thoracic outlet syndrome, Charcot-Marie-Tooth disease, and spinal muscular atrophy.

### Claim 33 (depends on 25)

The pharmaceutical composition for preventing and treating a disease according to claim 25, wherein the neurological disease is a degenerative brain disease.

### Claim 34 (depends on 33)

The pharmaceutical composition for preventing and treating a disease according to claim 33, wherein the degenerative brain disease is any one selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, mild cognitive impairment, cerebral amyloid angiopathy, Down syndrome, amyloid stroke, systemic amyloid disease, Dutch type amyloidosis, Niemann-Pick disease, senile dementia, amyotrophic lateral sclerosis, spinocerebellar atrophy, Tourette's syndrome, Friedrich's ataxia, Machado-Joseph's disease, Lewy body dementia, dystonia, progressive supranuclear palsy, and frontotemporal dementia.

### Claim 35 (depends on 25)

The pharmaceutical composition for preventing and treating a disease according to claim 25, wherein the autoimmune disease is any one selected from the group consisting of Crohn's disease, erythema, atopy, rheumatoid arthritis, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, type 1 diabetes mellitus, lupus, chronic fatigue syndrome, fibromyalgia, hypothyroidism and hyperthyroidism, scleroderma, Behcet's disease, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, Meniere's syndrome, Guillain-Barré syndrome, Sjogren's syndrome, vitiligo, endometriosis, psoriasis, vitiligo, systemic scleroderma, asthma, and ulcerative colitis.

### Claim 36

A method for producing natural killer cells, comprising:
inoculating induced pluripotent stem cells (iPSCs) as iPSCs or iPSC spheroids into a cell culture vessel so that 0.5 to 20 colonies are formed per 1 cm2 of cell culture vessel area and performing adhesion culture to produce iPSC colonies;
differentiating the iPSC colonies into mesodermal cells to produce mesodermal cells;
differentiating the mesodermal cells into hematopoietic stem cells to produce hematopoietic stem cells; and
differentiating the hematopoietic stem cells into natural killer cells to produce natural killer cells.

### Claim 37 (depends on 36)

The method for producing natural killer cells according to claim 36, wherein the production method further comprises a mass culture proliferation on the natural killer cells induced to differentiate.

### Claim 38 (depends on 36)

The method for producing natural killer cells according to claim 36, wherein the total number of stem cells on the start date of differentiation is 1×103 to 1×106 cells per 1 cm2 of cell culture vessel area.

### Claim 39 (depends on 36)

The method for producing natural killer cells according to claim 36, wherein the cells adhered to the culture vessel are not removed in the differentiating the mesodermal cells into hematopoietic stem cells.

### Claim 40 (depends on 1)

A use of the natural killer cell according to claim 1 for the prevention or treatment of a disease.

### Claim 41 (depends on 39)

The use for the prevention or treatment according to claim 39, wherein the disease is any one selected from the group consisting of an infectious disease, cancer, a neurological disease, and an autoimmune disease.

### Claim 42 (depends on 1)

A method for preventing or treating a disease, comprising: administering the natural killer cell according to claim 1.

### Claim 43 (depends on 42)

The method for preventing or treating a disease according to claim 42, wherein the disease is any one selected from the group consisting of an infectious disease, cancer, a neurological disease, and an autoimmune disease.

### Claim 44

A method for culturing stem cells, comprising: inoculating stem cells as iPSCs or iPSC spheroids into a cell culture vessel so that 0.5 to 20 colonies are formed per 1 cm2 of cell culture vessel area.

### Claim 45

A method for producing natural killer cells, comprising: differentiating hematopoietic stem cells into natural killer cells in the presence of feeder cells.
